Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Lilly Files Patent Suit against Hospira and Jiangsu Hansoh Pharma

publication date: Jan 31, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Eli Lilly & Co. has filed suit against Hospira Inc. (NYSE: HSP), seeking to block the company from selling a generic version of its cancer drug Gemzar. The generic Gemzar is made in China by Jiangsu Hansoh Pharmaceutical Co. Ltd. According to Lilly, the generic drug violates one of its Gemzar patents. More details....

Stock Symbol: (NYSE: LLY)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners